BIOMAT Database Logo BIOMAT Database Logo

Construction of a chimeric antibody with therapeutic potential for cancers which overexpress c-erbB-2. 1995

H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Department of Cell and Molecular Biology, Berlex Biosciences, Richmond, CA, USA.

We describe the chimerization of a monoclonal antibody directed against the c-erbB-2 protein using a novel PCR method for cloning immunoglobulin variable region genes. We also describe the characterization of the chimera and show its potential use for treating cancers which overexpress the c-erbB-2 protein. The genomic DNA fragments of heavy and light chain variable genes were cloned by PCR using uniquely designed primers which allowed for isolation of genes containing functional promoters, signal and coding sequences. The chimeric genes were then constructed by linking variable regions of murine genes to human constant gamma 1 and kappa genes. Expression of the chimeric immunoglobulin genes resulted in production of properly assembled chimeric antibody with improved biological properties.

UI MeSH Term Description Entries
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D007147 Immunoglobulin Light Chains Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule. Ig Light Chains,Immunoglobulins, Light-Chain,Immunoglobulin Light Chain,Immunoglobulin Light-Chain,Light-Chain Immunoglobulins,Chains, Ig Light,Chains, Immunoglobulin Light,Immunoglobulins, Light Chain,Light Chain Immunoglobulins,Light Chain, Immunoglobulin,Light Chains, Ig,Light Chains, Immunoglobulin,Light-Chain, Immunoglobulin
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning

Related Publications

H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Construction and expression of a functional chimeric receptor from PDGFr-beta and c-erbB-2.
May 1995, Biochemical Society transactions,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
June 1990, Oncogene,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
February 2003, Cell research,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Human tumor growth suppression by apoptosis induced with anti-ErbB-2 chimeric monoclonal antibody.
May 1998, Japanese journal of cancer research : Gann,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Clinical radioimmunolocalization with a rat monoclonal antibody directed against c-erbB-2.
January 1994, Cell biophysics,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
[int-2 and c-erbB-2 gene amplification in urological cancers].
December 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Human pituitary adenomas do not overexpress thec-erbB-2 oncoprotein.
December 1991, Endocrine pathology,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Establishment and characterization of mouse-human chimeric monoclonal antibody to erbB-2 product.
February 1994, Japanese journal of cancer research : Gann,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Eradication of c-erbB-2-Positive Ovarian Cancer Cells Mediated by Intracellular Expression of Anti-c-erbB-2 Antibody.
January 2001, Methods in molecular medicine,
H L Liu, and D L Parkes, and B C Langton, and J A Xuan, and M Longhi, and S S Elliger, and L A Chao, and M P McGrogan, and J W Brandis, and L K Shawver
Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.
September 2018, DNA and cell biology,
Copied contents to your clipboard!